224 related articles for article (PubMed ID: 28460431)
1. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ; Simmons AD; Lovejoy AF; Esfahani MS; Newman AM; Haringsma HJ; Kurtz DM; Stehr H; Scherer F; Karlovich CA; Harding TC; Durkin KA; Otterson GA; Purcell WT; Camidge DR; Goldman JW; Sequist LV; Piotrowska Z; Wakelee HA; Neal JW; Alizadeh AA; Diehn M
Nat Commun; 2016 Jun; 7():11815. PubMed ID: 27283993
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
[TBL] [Abstract][Full Text] [Related]
5. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.
Yang Y; Wu N; Shen J; Teixido C; Sun X; Lin Z; Qian X; Zou Z; Guan W; Yu L; Rosell R; Liu B; Wei J
Gastric Cancer; 2016 Jul; 19(3):778-88. PubMed ID: 26404902
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient.
Zhou S; Xu B; Qi L; Zhu D; Liu B; Wei J
Cancer Biol Ther; 2019; 20(1):15-20. PubMed ID: 30118648
[TBL] [Abstract][Full Text] [Related]
7. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.
Dong HJ; Li P; Wu CL; Zhou XY; Lu HJ; Zhou T
Lung Cancer; 2016 Dec; 102():118-121. PubMed ID: 27987579
[TBL] [Abstract][Full Text] [Related]
8. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
[TBL] [Abstract][Full Text] [Related]
9. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib-resistant
Shen B; Wu F; Ye J; Liang R; Wang R; Yu R; Wu X; Shao YW; Feng J
Future Oncol; 2019 Aug; 15(22):2585-2593. PubMed ID: 31339066
[No Abstract] [Full Text] [Related]
12. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
[TBL] [Abstract][Full Text] [Related]
13. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
[TBL] [Abstract][Full Text] [Related]
14. Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
Wang CG; Zeng DX; Huang JA; Jiang JH
Medicine (Baltimore); 2018 Jan; 97(1):e9021. PubMed ID: 29505507
[TBL] [Abstract][Full Text] [Related]
15. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?
Gouji T; Takashi S; Mitsuhiro T; Yukito I
J Thorac Oncol; 2014 Mar; 9(3):e27-8. PubMed ID: 24518097
[No Abstract] [Full Text] [Related]
18. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
